Validation of a reversed-phase HPLC method for directly quantifying the enantiomers of MDL 74 156, the primary metabolite of dolasetron mesylate, in human plasma
- 31 January 1997
- journal article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 15 (4) , 513-521
- https://doi.org/10.1016/s0731-7085(96)01827-4
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Pharmacology of the human metabolites of dolasetron, an antiemetic 5‐HT3 receptor antagonistDrug Development Research, 1995
- Stereoselectivity of the carbonyl reduction of dolasetron in rats, dogs, and humansChirality, 1995
- Determination of MDL 74,405, a synthetic analogue of α-tocopherol, in dog plasma and heart tissue by high-performance liquid chromatography with electrochemical detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1994
- Direct injection assay of drug enantiomers in serum on ovomucoid-bonded silica materials by liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1993
- Determination of dolasetron and its reduced metabolite in human plasma by GC—MS and LCJournal of Pharmaceutical and Biomedical Analysis, 1993
- Human dolasetron pharmacokinetics: II Absorption and disposition following single‐dose oral administration to normal male subjectsBiopharmaceutics & Drug Disposition, 1993
- Dolasetron mesylateDrugs of the Future, 1993
- Pharmacological properties of dolasetron, a potent and selective antagonist at 5‐HT3 receptorsDrug Development Research, 1993
- Human dolasetron pharmacokinetics: I. Disposition following single‐dose intravenous administration to normal male subjectsBiopharmaceutics & Drug Disposition, 1992
- Characterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma × glioma cellsEuropean Journal of Pharmacology, 1992